Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

NCT07411599 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Peritoneal Metastases
Carcinomatosis

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Cetuximab
DRUG: NK Cells

Sponsor

M.D. Anderson Cancer Center